CCR2 and pancreatic ductal adenocarcinoma: A Phase Ib Study of the CCR2 Inhibitor PF-04136309 in Combination with Nab-Paclitaxel and Gemcitabine for Patients with Metastatic Pancreatic Ductal Adenocarcinoma.